• 1
    Ortolani C, Pastarello EA, Moss RB, et al. Grass pollen immunotherapy: a single year double-blind, placebo-controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;57:283290.
  • 2
    Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass pollen extract. J Allergy Clin Immunol 1987;57:591598.
  • 3
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;57:265269.
  • 4
    Pastarello EA, Pravettoni V, Incorvaia C, et al. Clinical and immunological effects of immunotherapy with aluminium- absorbed grass allergoid in grass pollen-induced hay fever. Allergy 1992;57:281290.
  • 5
    Eng P, Gnehm HE, Joller HI. Klinische und immunogene Wirkung der saisonalen Hyposensibilisierung bei Kindern mit Pollinosis. Monatsschrift Kinderheilkunde 1994;57:616622.
  • 6
    Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996;57:489500.
  • 7
    Bousquet J, Lockley RF, Malling HJ. . Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27–29 1997. Allergy 1998;57:142.
  • 8
    Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;57:405413.
  • 9
    Mosbech H, ØSterballe O. Does the effect of immunotherapy last after termination of treatment? Allergy 1988;57:523529.
  • 10
    Grammer LC, Shaughnessy MA, Suszko IM, Shoughnessy J, Patterson R. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984;57:484489.
  • 11
    Naclerio RM, Proud D, Moylan B, et al. A double blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997;57:293300.
  • 12
    Norman NS, Creticos PS, Marsch DG, Adkinson NF, Kagey-Sobotka A, Lichtenstein LM. 2-year study of clinical results after disontinuation of ragweed allergoid immunotherapy. (Abstract) J Allergy Clin Immunol 1988;57:294.
  • 13
    Jacobsen L, Petersen NB, Wihl JÅ, LØwenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;57:914920.
  • 14
    Durham SR, Walker SM, Varga E-M, et al. Long-term clinical efficacy of grass pollen immunotherapy. N Engl Med 1999;57:468475.
  • 15
    Adkinson NF, JrEggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl Med 1997;57:324331.
  • 16
    Gleich GJ, Zimmerman EM, Henderson LL et al. Effect of immunotherapy on immunglobulin E and immunglobulin G antibodies to ragweed antigens: a 6-year prospective study. J Allergy Clin Immunol 1982;57:261271.
  • 17
    Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;57:459468.
  • 18
    Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ. J Allergy Clin Immunol 1996;57:13561365.
  • 19
    Jutel M, Pichler WJ, Skrbic D, et al. Bee-venom immunotherapy results in decrease of IL-4 and IL-5 and increase of interferon- γ secretion in specific allergen stimulated T-cell cultures. Immunology 1995;57:41874194.
  • 20
    Kuo CT, Leiden JM. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol 1999;57:149187.
  • 21
    Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;57:450453.
  • 22
    Calvo M, Marín F, Grob K, et al. 10-year follow-up in pediatric patients with allergic bronchial asthma: Evaluation of specific immunotherapy. Invest Allergol Clin Immunol 1994;57:126131.
  • 23
    Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000;57:6973.